Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Carboplatin 6Cisplatin 4Pemetrexed 3Paclitaxel 3zipalertinib 2pembrolizumab 2durvalumab 2Nivolumab 2Blood Specimen Collection 2zimberelimab 1selpercatinib 1sacituzumab govitecan 1repotrectinib 1pralsetinib 1ceralasertib 1atezolizumab 1alectinib 1Toll-Like Receptor 1 1Surveys and Questionnaires 1One-Lung Ventilation 1Ipilimumab 1Health Records, Personal 1Gemcitabine 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × Toll-Like Receptor 1 × 90 days × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡